Last reviewed · How we verify

Mineral trioxide aggregate

Universidad de los Andes, Chile · FDA-approved active Small molecule

Mineral trioxide aggregate is a Small molecule drug developed by Universidad de los Andes, Chile. It is currently FDA-approved for Root canal obturation and sealing, Perforation repair in endodontic treatment, Apexification in immature teeth. Also known as: MTA Pro Root, MTA pulpotomy, MTA, (ProRoot MTA).

Mineral trioxide aggregate (MTA) is a biocompatible cement that sets through a hydration reaction, creating a hard matrix that seals and promotes healing in endodontic and dental applications.

Mineral trioxide aggregate (MTA) is a biocompatible cement that sets through a hydration reaction, creating a hard matrix that seals and promotes healing in dental and endodontic applications. Used for Pulp capping and pulpotomy in vital teeth, Apical barrier formation in immature permanent teeth with open apices, Repair of root perforations.

At a glance

Generic nameMineral trioxide aggregate
Also known asMTA Pro Root, MTA pulpotomy, MTA, (ProRoot MTA)
SponsorUniversidad de los Andes, Chile
ModalitySmall molecule
Therapeutic areaDentistry/Endodontics
PhaseFDA-approved

Mechanism of action

MTA consists of Portland cement and bismuth oxide, which hydrate to form calcium silicate hydrate and calcium hydroxide. These products create a biocompatible, antimicrobial barrier that promotes periapical healing and hard tissue formation. It is used primarily in endodontics for root canal treatment, perforation repair, and apexification.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mineral trioxide aggregate

What is Mineral trioxide aggregate?

Mineral trioxide aggregate is a Small molecule drug developed by Universidad de los Andes, Chile, indicated for Root canal obturation and sealing, Perforation repair in endodontic treatment, Apexification in immature teeth.

How does Mineral trioxide aggregate work?

Mineral trioxide aggregate (MTA) is a biocompatible cement that sets through a hydration reaction, creating a hard matrix that seals and promotes healing in endodontic and dental applications.

What is Mineral trioxide aggregate used for?

Mineral trioxide aggregate is indicated for Root canal obturation and sealing, Perforation repair in endodontic treatment, Apexification in immature teeth, Pulp capping and pulpotomy.

Who makes Mineral trioxide aggregate?

Mineral trioxide aggregate is developed and marketed by Universidad de los Andes, Chile (see full Universidad de los Andes, Chile pipeline at /company/universidad-de-los-andes-chile).

Is Mineral trioxide aggregate also known as anything else?

Mineral trioxide aggregate is also known as MTA Pro Root, MTA pulpotomy, MTA, (ProRoot MTA).

What development phase is Mineral trioxide aggregate in?

Mineral trioxide aggregate is FDA-approved (marketed).

What are the side effects of Mineral trioxide aggregate?

Common side effects of Mineral trioxide aggregate include Discoloration of tooth structure, Difficulty in removal if over-extended, Allergic reaction (rare).

Related